Blood:遗传-转录组学分析明确关键转录因子是人红白血病的驱动因素

2020-05-12 QQY MedSci原创

急性红细胞白血病(AML-M6或AEL) 是一种罕见的侵袭性血液恶性肿瘤。既往研究表明,AEL白血病细胞通常携带已知的AML相关癌基因的复杂核型和突变。

急性红细胞白血病(AML-M6或AEL) 是一种罕见的侵袭性血液恶性肿瘤。既往研究表明,AEL白血病细胞通常携带已知的AML相关癌基因的复杂核型和突变。

为了更好地定义驱动红系表型的潜在分子机制,研究人员对33例AEL样本系列进行研究,这些样本代表了AEL的三个遗传亚组,包括TP53突变、表观遗传调控子突变(如DNMT3A、TET2或IDH2)和未定义的低突变负荷的病例。

研究人员建立了一个基于红系 vs 髓系的转录组学的“空间”,在该“空间”中,与上述分子亚组无关,大多数AEL样品表现出与非M6 AML和骨髓增生异常综合征样品不同的独特定位。值得注意的是,超过25%的AEL患者(包括在基因上不确定的亚组中)显示出关键转录调节因子的异常表达,包括SKI、ERG和ETO2。这些因子在小鼠红系前体细胞中的异位表达阻碍了红系体外分化,导致永生化,与GATA1结合位点的染色质可及性降低以及对GATA1活性的功能干扰有关。

体内模型显示,致命的红系、红系/髓样混合或其他恶性肿瘤的发生,取决于表达AEL相关变异的细胞群。

总而言之,本研究提示,AEL是一种具有红系同一性的分子异质性疾病,部分原因是造血干细胞或祖细胞中关键的红系转录因子的异常活性。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1747392, encodeId=fdbb1e47392be, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Mon Feb 01 16:08:54 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028390, encodeId=5239202839091, content=<a href='/topic/show?id=ba7e10150e84' target=_blank style='color:#2F92EE;'>#驱动因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101507, encryptionId=ba7e10150e84, topicName=驱动因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Mon Sep 21 05:08:54 CST 2020, time=2020-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420198, encodeId=9800142019899, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Thu May 14 12:08:54 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537496, encodeId=9fe5153e496db, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Thu May 14 12:08:54 CST 2020, time=2020-05-14, status=1, ipAttribution=)]
    2021-02-01 mjldent
  2. [GetPortalCommentsPageByObjectIdResponse(id=1747392, encodeId=fdbb1e47392be, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Mon Feb 01 16:08:54 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028390, encodeId=5239202839091, content=<a href='/topic/show?id=ba7e10150e84' target=_blank style='color:#2F92EE;'>#驱动因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101507, encryptionId=ba7e10150e84, topicName=驱动因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Mon Sep 21 05:08:54 CST 2020, time=2020-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420198, encodeId=9800142019899, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Thu May 14 12:08:54 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537496, encodeId=9fe5153e496db, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Thu May 14 12:08:54 CST 2020, time=2020-05-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1747392, encodeId=fdbb1e47392be, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Mon Feb 01 16:08:54 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028390, encodeId=5239202839091, content=<a href='/topic/show?id=ba7e10150e84' target=_blank style='color:#2F92EE;'>#驱动因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101507, encryptionId=ba7e10150e84, topicName=驱动因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Mon Sep 21 05:08:54 CST 2020, time=2020-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420198, encodeId=9800142019899, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Thu May 14 12:08:54 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537496, encodeId=9fe5153e496db, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Thu May 14 12:08:54 CST 2020, time=2020-05-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1747392, encodeId=fdbb1e47392be, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Mon Feb 01 16:08:54 CST 2021, time=2021-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028390, encodeId=5239202839091, content=<a href='/topic/show?id=ba7e10150e84' target=_blank style='color:#2F92EE;'>#驱动因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101507, encryptionId=ba7e10150e84, topicName=驱动因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Mon Sep 21 05:08:54 CST 2020, time=2020-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420198, encodeId=9800142019899, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Thu May 14 12:08:54 CST 2020, time=2020-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537496, encodeId=9fe5153e496db, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Thu May 14 12:08:54 CST 2020, time=2020-05-14, status=1, ipAttribution=)]

相关资讯

Nature:FOX转录因子突变方式诠释前列腺癌治疗新靶点

基因突变是物种不断进化的动力泉源,与此同时基因突变也可能导致癌症。人体中基因变异的方式各有不同,如今密歇根大学罗盖尔癌症中心的研究人员发现了基因突变的三种方式。该研究结果发表在《Nature》杂志上。

Sci Rep:前列腺癌中ETS转录因子ETV1和TGF-β调控的SMAD蛋白关系研究

ETS转录因子ETV1在恶性前列腺癌中经常过表达,也是前列腺癌的病因之一。相应地,前列腺特异性过表达ETV1的转基因小鼠能够发生前列腺上皮内瘤样病变。然而,这些小鼠中却并不能发展为恶性肿瘤阶段,表明了抑制途径可能阻止了ETV1的完整致瘤作用。最近,有研究人员表明了TGF-β/SMAD信号就是上述的抑制途径。首先,研究人员发现ETV1能够与SMAD4形成复合物。其次,SMAD2、SMAD3和SMAD

J Dent Res:Mdm2通过泛素化Dlx3和p53促进牙乳头细胞成牙本质细胞样分化

牙本质是牙齿的重要结构成分。成牙本质细胞分化是保证正常牙本质形成的必不可少的生物学过程,该过程由各种蛋白质精确调控。鼠双微体基因(Mdm2)是一种E3泛素连接酶,在成骨细胞和成肌细胞等不同细胞类型的分

Lab Invest:视网膜相关孤核受体α(RORα)缺陷表现出睾丸形态缺陷

视网膜相关孤核受体(已报道的睾丸中转录因子)在睾丸功能中的作用仍旧不清楚。最近,有研究人员在RORα缺陷小鼠中,使用光学、电子显微镜和免疫组化染色对睾丸结构的变化进行了定性和定量分析。研究发现,变异小鼠睾丸中最为明显的变化包括生殖功能低下,间质组织体积比例和间质细胞数量明显减少,生精管直径和上皮高度显著减少,生精小管上皮空泡化,肥大细胞出现,精子出现延迟征象以及精子形态发生变化。更多的是,突变小鼠

JACC:KLF15-Wnt信号依赖的心肌重构研究

在应激状态下,心肌细胞(CM)和血管细胞(VC)胎儿重编程的结合最终导致终末期心力衰竭的机制尚不完全清楚,既往研究报道KLF15是CM肥厚的重要调节因子。本研究的目的旨在评估转录因子KLF15对心衰发展的影响。通过基因敲除小鼠模型,本研究发现Wnt信号通路在出生后的病理组织重塑中对KLF15有转录抑制作用。作者进一步揭示了由CM细胞间交互引起的血管稳态,且与KLF15的减少和Wnt的激活相关。另外

Blood:转录因子IKZF5突变导致血小板减少

中心点:转录因子IKZF5突变可引发常染色体显性遗传的血小板减少症和α颗粒缺乏。虽然IKZF5在造血系细胞中表达,但IKZF5表达失调仅限于巨核细胞系。摘要:为选择遗传性血小板减少症的新发病因,研究人员对NIHR BioResource招募的13 037位个体的全基因组测序(WGS)信息进行遗传关联分析,其中包括233例孤立性血小板减少症。研究人员发现转录因子编码基因IKZF5上的稀有突变与血小板